作者
Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E Singer, Werner Hacke, Günter Breithardt, Jonathan L Halperin, Graeme J Hankey, Jonathan P Piccini, Richard C Becker, Christopher C Nessel, John F Paolini, Scott D Berkowitz, Keith AA Fox, Robert M Califf, Rocket AF Steering Committee
发表日期
2011/9/8
期刊
New England Journal of Medicine
卷号
365
期号
10
页码范围
883-891
出版商
Massachusetts Medical Society
简介
Background
The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.
Methods
In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism.
Results
In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the warfarin group (2.2% per year) (hazard ratio in the rivaroxaban group, 0.79; 95% confidence interval [CI], 0.66 …
引用总数
学术搜索中的文章
MR Patel, KW Mahaffey, J Garg, G Pan, DE Singer… - New England Journal of Medicine, 2011
GJ Hankey, Rocket AF Investigators - The New England journal of medicine, 2011